World Health Organization & Serum Institute of India

World Health Organization: The World Health Organization recommended prioritizing three experimental treatments and several vaccine candidates for the Bundibugyo strain of Ebola, and is working with authorities to design and implement clinical trials.

Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.

World Health Organization: Leading the international response, declaring a PHEIC, recommending vaccine trials, and adding a diagnostic test to its Emergency Use Listing. Its credibility is tied to the success of the response.

Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.

World Health Organization: Coordinating vaccine allocation and clinical trials, but facing uncertainty about vaccine efficacy against the current strain. Its guidance is critical for the response.

Serum Institute of India: Manufactured 620,000 doses of the Oxford vaccine candidate, positioning itself for large-scale production if trials succeed.

World Health Organization: The World Health Organization (WHO) has declared the outbreak a public health emergency and is involved in monitoring cases and coordinating the global health response.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

World Health Organization: The World Health Organization announced a $518 million plan to combat the Ebola outbreak, providing strategic guidance and financial commitment to halt its spread.

Serum Institute of India: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate targeting the Bundibugyo strain of Ebola, in collaboration with the University of Oxford and CEPI, to address the lack of an approved vaccine for this variant.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.

World Health Organization: Provided estimates on vaccine impact; prequalification role.

Serum Institute of India: Manufacturing partner investing over $100 million; strengthens its vaccine portfolio and global reach.

World Health Organization: PAHO can procure QDENGA through its procurement mechanisms, facilitating access in the Americas.

Serum Institute of India: Serum Institute of India is among the domestic manufacturers with dengue vaccine candidates in development, indicating potential future competition.